IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 289 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,637,933 | -25.7% | 55,349 | -32.4% | 0.01% | +9.1% |
Q1 2024 | $3,548,067 | -14.3% | 81,847 | 0.0% | 0.01% | -21.4% |
Q4 2023 | $4,140,640 | +18.2% | 81,847 | +5.9% | 0.01% | +7.7% |
Q3 2023 | $3,504,559 | +6.2% | 77,261 | -3.9% | 0.01% | +18.2% |
Q2 2023 | $3,300,166 | +14.8% | 80,433 | 0.0% | 0.01% | +10.0% |
Q1 2023 | $2,874,675 | -5.4% | 80,433 | 0.0% | 0.01% | -9.1% |
Q4 2022 | $3,037,954 | -14.6% | 80,433 | 0.0% | 0.01% | -21.4% |
Q3 2022 | $3,558,000 | +19.5% | 80,433 | 0.0% | 0.01% | +27.3% |
Q2 2022 | $2,978,000 | -9.5% | 80,433 | -9.5% | 0.01% | +10.0% |
Q1 2022 | $3,292,000 | +13.6% | 88,879 | -6.7% | 0.01% | +25.0% |
Q4 2021 | $2,898,000 | -0.9% | 95,234 | +9.2% | 0.01% | -11.1% |
Q3 2021 | $2,925,000 | -15.5% | 87,216 | +0.5% | 0.01% | -18.2% |
Q2 2021 | $3,460,000 | -9.4% | 86,745 | +2.1% | 0.01% | -15.4% |
Q1 2021 | $3,818,000 | -29.8% | 84,923 | -11.7% | 0.01% | -31.6% |
Q4 2020 | $5,438,000 | +17.4% | 96,182 | -1.5% | 0.02% | +5.6% |
Q3 2020 | $4,634,000 | -20.5% | 97,657 | -1.2% | 0.02% | -25.0% |
Q2 2020 | $5,831,000 | +21.7% | 98,892 | -2.4% | 0.02% | +4.3% |
Q1 2020 | $4,792,000 | -21.7% | 101,352 | 0.0% | 0.02% | 0.0% |
Q4 2019 | $6,123,000 | -2.3% | 101,352 | -3.1% | 0.02% | -4.2% |
Q3 2019 | $6,267,000 | -30.4% | 104,600 | -25.3% | 0.02% | -27.3% |
Q2 2019 | $8,998,000 | -20.8% | 140,000 | 0.0% | 0.03% | -23.3% |
Q1 2019 | $11,364,000 | +110.2% | 140,000 | +40.0% | 0.04% | +87.0% |
Q4 2018 | $5,406,000 | +4.8% | 100,000 | 0.0% | 0.02% | +21.1% |
Q3 2018 | $5,158,000 | +23.8% | 100,000 | 0.0% | 0.02% | +18.8% |
Q2 2018 | $4,167,000 | -5.5% | 100,000 | 0.0% | 0.02% | -5.9% |
Q1 2018 | $4,408,000 | -12.4% | 100,000 | 0.0% | 0.02% | -10.5% |
Q4 2017 | $5,030,000 | -0.8% | 100,000 | 0.0% | 0.02% | -5.0% |
Q3 2017 | $5,070,000 | -0.3% | 100,000 | 0.0% | 0.02% | -4.8% |
Q2 2017 | $5,087,000 | +26.5% | 100,000 | 0.0% | 0.02% | +23.5% |
Q1 2017 | $4,020,000 | -16.0% | 100,000 | 0.0% | 0.02% | -19.0% |
Q4 2016 | $4,783,000 | +30.5% | 100,000 | 0.0% | 0.02% | +31.2% |
Q3 2016 | $3,664,000 | +57.3% | 100,000 | 0.0% | 0.02% | +45.5% |
Q2 2016 | $2,329,000 | -42.5% | 100,000 | 0.0% | 0.01% | -38.9% |
Q1 2016 | $4,050,000 | -67.3% | 100,000 | -50.0% | 0.02% | -30.8% |
Q4 2015 | $12,386,000 | – | 200,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |